HDG... Amarin creating their own AG, in competition with Generic companies , which offer exclusivity to pharmacies and pharmacy benefit plans for their large stable of generic drugs would mean the necessity for Amarin to drastically lower their prices for Vascepa.
At that point, Amarin creating Vascepa as a dietary supplement...and distributing it globally as such, might be a better choice.
HDGabor, what do you see is the best way AMRN can compete and increase sales and adoption of Vascepa in the US? Do you think a branded generic or AG strategy will overcome auto switching and generic preference policies and practices to turn the tide in AMRNs favor? Do you favor the current plan of negotiating exclusivity with branded V is a better option or something else? Lastly, could AMRN use the excess API to launch a DS EPA to compete with other DS EPA products to help support pharmaceutical sales of Vascepa/Vaskepa. TIA
News 
Market Data 
Discover 
